C3L-02170
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 73.14715948
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.660
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- IL6_JAK_STAT3_SIGNALING+0.550
- INFLAMMATORY_RESPONSE+0.550
- ANGIOGENESIS+0.540
- COAGULATION+0.460
- ALLOGRAFT_REJECTION+0.430
- TGF_BETA_SIGNALING+0.390
- COMPLEMENT+0.380
- IL2_STAT5_SIGNALING+0.380
Top 10 suppressed
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.440
- MYC_TARGETS_V1-0.430
- OXIDATIVE_PHOSPHORYLATION-0.410
- DNA_REPAIR-0.330
- PROTEIN_SECRETION-0.320
- MYC_TARGETS_V2-0.250
- MITOTIC_SPINDLE-0.180
- GLYCOLYSIS-0.160
- PEROXISOME-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797296 | — | cohortMD2 | 0.941 |
| 2 | SRR6013602 | — | cohortMD2 | 0.940 |
| 3 | C3L-02164 | — | cohortMD2 | 0.937 |
| 4 | BS_GDHH6T5A | Neurofibroma | — | 0.934 |
| 5 | SRR26320074 | — | — | 0.933 |
| 6 | BS_G1Y281HX | Neuroblastoma | — | 0.933 |
| 7 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.928 |
| 8 | 20120155.TNBC | — | D | 0.926 |
| 9 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.925 |
| 10 | TCGA-XF-AAN8-01A-11R-A42T-07 | — | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.660 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |